
    
      The primary objective of the study is evaluate the impact of the molecular assay prediction
      on the efficacy of therapy for patients with carcinoma of unknown primary site (CUP).
      Investigators will use tumor profiling results to direct standard, site-specific first-line
      therapy for patients with CUP.
    
  